Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CLL-1 CAR-T cells |
Synonyms | |
Therapy Description |
CLL-1 CAR-T cells consist of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CLL1 and contains CD28 and CD137 (4-1BB) costimulatory and CD3 zeta signaling domains, which potentially induces lysis of tumor cells expressing CLL1 and reduces tumor burden (PMID: 29316944). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CLL-1 CAR-T cells | CLL1 CAR-T cells|anti-CLL1 CART cells | CLL-1 CAR-T cells consist of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CLL1 and contains CD28 and CD137 (4-1BB) costimulatory and CD3 zeta signaling domains, which potentially induces lysis of tumor cells expressing CLL1 and reduces tumor burden (PMID: 29316944). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04219163 | Phase I | CLL-1 CAR-T cells | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | Recruiting | USA | 0 |